Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
28 Results for "
HGC27
" in MedChemExpress (MCE) Product Catalog:
Products (28)
28 Results for "HGC27" in MCE Product Catalog:
6
1
1 Cited Publications
Cat. No.: HY-147803
Purity: 98.07%
Target:
Research Areas:
TrxR-IN-5 (compound 4f) is a potent TrxR (thioredoxin reductase) inhibitor, with an IC50 of 0.16 μM. TrxR-IN-5 increases the levels of ROS, thus leading to potent antiproliferative effects. TrxR-IN-5 exhibits prominent anticacer and anti-metastasis effects .
Target:
Research Areas:
Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
M435-1279 is a UBE2T inhibitor. M435-1279 inhibits the Wnt/β-catenin signaling pathway hyperactivation through blocking UBE2T-mediated degradation of RACK1 .
Cat. No.: HY-W040150
CAS No.: 77058-74-3
Target:
Research Areas:
24S,25-Epoxycholesterol is an agonist for Liver X Receptor (LXR). 24S,25-Epoxycholesterol exhibits properties in regulating the cholesterol efflux , inhibiting tumor growth against gastric cancer and glioblastoma and inducing apoptosis in BMMC cells .
Cat. No.: HY-156418
CAS No.: 2787598-01-8
Research Areas:
KY386 is a DHX33 helicase inhibitor with an IC50 of 0.019 μM. KY386 inhibits the cell viability of various cancer cells. KY386 induces ferroptosis in cancer cells, and induces apoptosis in some cancer cell lines. KY386 increases the intracellular levels of ROS, LPO and Fe 2+, and decreases the level of GSH in cancer cells . KY386 inhibits the growth of gastric cancer and colon cancer xenografts in nude mice. KY386 is applicable to the related research on liver cancer, lung cancer, pancreatic cancer, colorectal cancer, gastric cancer, breast cancer, leukemia, renal cancer, prostate cancer, esophageal cancer, cervical cancer, brain cancer (glioblastoma) and melanoma .
Cat. No.: HY-174461
PROTAC PI3Kα degrader-1 is a PI3Kα PROTAC degrader (DC50 = 0.08 μM), demonstrating good selectivity for PI3Kα degradation over PI3Kβ, PI3Kγ, and PI3Kδ. PROTAC PI3Kα degrader-1 effectively degrades PI3Kα in a time- and concentration-dependent, over PI3Kβ, PI3Ky and PI3Kδ, and potently inhibited the phosphorylation of AKT at the Ser473site. PROTAC PI3Kα degrader-1 shows significant in vivo anticancer efficacy in HGC-27 and DOHH2 xenograft models .
Cat. No.: HY-116038
CAS No.: 21688-61-9
Target:
Cat. No.: HY-170935
SRSF1-IN-1 is a SRSF1 inhibitor. SRSF1-IN-1 inhibits SRSF1 expression, thereby modulating the splicing of Bcl-x pre-mRNA. SRSF1-IN-1 inhibits the proliferation of various cancer cells. SRSF1-IN-1 induces apoptosis in gastric cancer cells, reduces Bcl-xl expression, and upregulates cleaved PARP and caspase 3. SRSF1-IN-1 induces autophagy and promotes cell death. SRSF1-IN-1 exhibits anti-tumor activity in a mouse gastric cancer xenograft model. SRSF1-IN-1 can be used for the research of various cancers including liver cancer, gastric cancer, breast cancer, colon cancer, glioma, and melanoma .
Cat. No.: HY-115974
CAS No.: 3052544-28-9
Target:
Research Areas:
GRPR antagonist-1 is a potent gastrin releasing peptide receptor (GRPR) antagonist, having the cytotoxicity against certain cancer cells (IC50 of 4.97, 4.36 and 3.40 μM in PC3, Pan02 and HGC-27 cells, respectively). GRPR antagonist-1 inhibits HGC-27 cell viability by decreasing the Bcl-2 level and increasing the Bax level, causing apoptosis, with anticancer activity .
Cat. No.: HY-N3741
CAS No.: 18296-45-2
Synonyms: Didrovaltratum
Cat. No.: HY-132972
CAS No.: 2866261-50-7
TrxR-IN-2 is a thioredoxin reductase (TrxR) inhibitor. TrxR-IN-2 increases reactive oxidative species (ROS) levels and decreases mitochondrial transmembrane potential levels. TrxR-IN-2 triggers DNA damage via H2AX regulation, and induces autophagy via LC3, beclin-1, and p62 regulation. TrxR-IN-2 can be used for the research of drug-resistant hepatocellular carcinoma[1].
Cat. No.: HY-175733
CAS No.: 3105591-09-8
Target:
Research Areas:
CQ3196 is an orally active RIOK2 inhibitor with a Kd of 14 nM. CQ3196 effectively inhibits the ATPase activity of RIOK2, with an IC50 value of 72 nM. CQ3196 inhibits cell proliferation and colony formation in gastric cancer cell lines. CQ3196 induces cell apoptosis in HGC-27 and AGS cells. CQ3196 suppresses downstream signal pathway of RIOK2. CQ3196 reduces phosphorylation of mTOR and AKT. CQ3196 modulates ribosome function and protein synthesis. CQ3196 inhibits tumor growth and can be used for gastric cancer invtro and invivo research .
Cat. No.: HY-115975
CAS No.: 3052544-42-7
Target:
Research Areas:
GRPR antagonist-2 is a potent gastrin releasing peptide receptor (GRPR) antagonist, having the cytotoxicity against certain cancer cells (IC50 of 0.77 and 2.5 μM in HGC-27 and Pan02 cells, respectively). Anticancer activity .
Cat. No.: HY-161301
CAS No.: 3030012-25-7
PI3K-IN-52 (compound cis 6g) is a potent inhibitor of PI3K, with IC50 of 0.23 μM in HGC-27 cells. PI3K-IN-52 plays an important role in cancer research[1].
Cat. No.: HY-146743
CAS No.: 2757145-67-6
Antitumor agent-53 is a potent antitumor agent. Antitumor agent-53 induces cell cycle arrest at the G2/M phase. Antitumor agent-53 inhibits the PI3K/AKT pathway to induce the apoptosis of HGC-27 cells. Antitumor agent-53 has the potential for the research of gastrointestinal tumors .
Cat. No.: HY-178513
Research Areas:
Anti-MRSA agent 38 is a broad-spectrum antibacterial agent (MIC = 0.0625-2 µg/mL). Anti-MRSA agent 38 can inhibit ribosomal protein synthesis. Anti-MRSA agent 38 exerts multiple bactericidal effects by disrupting bacterial membrane structure and inducing ROS accumulation. Anti-MRSA agent 38 can selectively kill tumor cells, such as HGC-27 (IC50 = 0.86 µM), MRC-5 (IC50 = 5.52 µM), and RPC (IC50 = 6.09 µM) cells. Anti-MRSA agent 38 can be used to study infectious diseases such as bacterial infection .
Cat. No.: HY-168044
ALKBH1-IN-3 is a potent DNA N6-methyladenine (6mA) demethylase ALKBH1 inhibitor. ALKBH1-IN-3 increases the abundance of 6mA, inhibits cell viability and upregulates the AMP-activated protein kinase (AMPK) signaling pathway in gastric cancer cell lines HGC27 and AGS. ALKBH1-IN-3 is promising for research of cancers, including gastric cancer .
Cat. No.: HY-168519
CAS No.: 3055766-74-7
STAT3-IN-36 (compound 11g) is a triple-target inhibitor targeting LRPPRC, STAT3, and CDK1 with anticancer activity. STAT3-IN-36 binds to LRPPRC, STAT3, and CDK1, exerting a stronger anticancer effect than TMF (HY-N6818) or Capecitabine (HY-B0016). STAT3-IN-36 inhibits HGC27 cells with IC50 1.8 μM. .
Cat. No.: HY-149521
PI3K-IN-47 (Compound 27) is a bivalent PI3K inhibitor (IC50: 0.44 nM for PI3Kα, 7.18 nM, 13.92 nM, 22.83 nM for PI3Kβ, PI3Kγ, PI3Kδ). PI3K-IN-47 induces cell cycle arrest in G1 phase, inhibits colony formation and cell migration. PI3K-IN-47 inhibits tumor growth in HGC-27 xenograft mice .
Cat. No.: HY-176237
CAS No.: 3077970-44-3
Nampt-IN-16 (Compound 9a) is an orally active NAMPT inhibitor with an IC50 of 0.15 μM. Nampt-IN-16 can reduce intracellular NAD + and ATP levels. Nampt-IN-16 can inhibit the proliferation, migration, and invasion, induce cell cycle arrest and apoptosis, and alter cellular metabolism of gastric cancer cells. Nampt-IN-16 can be used in the research of tumors such as gastric cancer .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
